Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: A quantitative microdialysis study

Pharmaceutical Research

Volumn 16, Issue 5, 1999, Pages 637-642

  Hesselink, Mayke B ^a,b   De Boer, Bert G ^b   Breimer, Douwe D ^b   Danysz, Wojciech ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Aminoadamantanes; In vivo recovery; Microdialysis

Indexed keywords

AMANTADINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CELL COMPARTMENTALIZATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIALYSIS MEMBRANE; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG PENETRATION; EXTRACELLULAR SPACE; MICRODIALYSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RAT; RECEPTOR BINDING;

AMANTADINE; ANIMALS; BIOLOGICAL TRANSPORT; BRAIN CHEMISTRY; DOPAMINE AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; EXTRACELLULAR SPACE; MALE; MEMANTINE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0008996143     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018856020583     Document Type: Article

References (27)

1. 1. J. B. Justice Jr. Quantitative microdialysis of neurotransmitters, J. Neurosci. Methods 48:263-276 (1993).
2. 2. W. F. Elmquist and R. J. Sawchuk. Application of microdialysis in pharmacokinetic studies, Pharm. Res. 14:267-288 (1997).
3. 3. M. Hammarlund-Udenaes, L. K. Paalzow, and E. C. M. de Lange. Drug equilibrium across the blood-brain barrier-Pharmacokinetic considerations based on the microdialysis method, Pharm. Res. 14:128-134 (1997).
4. 4. Y. Wang and D. F. Welty. The simultaneous estimation of the influx and efflux blood-brain permeabilities of gabapentin using a microdialysis-pharmacokinetic approach., Pharma. Res. 13:398-403 (1996).
5. 5. U. E. Honegger, G. Quack, and U. N. Wiesmann. Evidence for lysosomotropism of memantine in cultured human cells - cellularkinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission, Pharmacol. Toxicol. 73:202-208 (1993).
6. 6. Z. Yang, R. C. Brundage, and R. H. Barbhaiya. Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat, Pharm. Res. 14:865-872 (1997).
7. 7. H. Benveniste and P. C. Huttemeier. Microdialysis-theory and application, Prog. Neurobiol. 35:195-215 (1990).
8. 8. N. Lindefors, G. Amberg, and U. Ungerstedt. Intracerebral microdialysis: I. Experimental studies of diffusion kinetics, J. Pharmacol. Meth. 22:141-156 (1989).
9. 9. H. Benveniste and A. J. Hansen. Practical aspects of using microdialysis for determination of brain interstitial concentrations. In T. E. Robinson and J. B. Justice JR. (eds), Microdialysis in the Neuroscience, Elsevier, Amsterdam, 1991, pp. 81-100.
10. 10. P. Lönnroth, P. A. Jansson, and U. Smith. A microdialysis method allowing characterization of intercellular water space in humans, Am. J. Physiol. 253:E228-E231 (1987).
11. 11. I. Jacobson, M. Sandberg, and A. Hamberger. Mass transfer in brain dialysis devices-A new method for the estimation of extracellular amino acids concentration, J. Neurosci. Methods 15:263-268 (1985).
12. 12. L. Stahle. The use of microdialysis in pharmacokinetics and pharmacodynamics. In T. E. Robinson and J. B. Justice JR. (eds), Microdialysis in neurosciences, Techniques in the behavioral and neural sciences, Vol. 7, Elsevier, New York, 1991, pp. 155-188.
13. 13. J. Komhuber and G. Quack. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man, Neurosci. Lett. 195:137-139 (1995).
14. 14. W. Danysz, C. G. Parsons, J. Kornhuber, W. J. Schmidt, and G. Quack. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies, Neurosci. Biobehav. Rev. 21:455-468 (1997).
15. 15. M. Misztal, T. Frankiewicz, C. G. Parsons, and W. Danysz. Learning deficits induced by chronic intraventricular infusion of quinolinic acid-protection by MK-801 and memantine, Eur. J. Pharmacol. 296:1-8 (1996).
16. 16. A. Vezzani, R. Serafini, M. A. Stasi, S. Caccia, I. Conti, R. V. Tridico, and R. Samanin. Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats, J. Pharmacol. Exp. Ther. 249:278-283 (1989).
17. 17. P. H. Schwartz and C. G. Wasterlain. Determination of serum and brain concentrations of neuroprotective and non-neuroprotective doses of MK-801, J. Neurol. Sci. 115:26-31 (1993).
18. 18. G. K. Steinberg, D. Kunis, J. Saleh, and R. Delapaz. Protection after transient focal cerebral ischemia by the N-methyl-D-aspartate antagonist dextrorphan is dependent upon plasma and brain levels, J. Cereb. Blood Flow Metab. 11:1015-1024 (1991).
19. 19. P. Hartvig, J. Valtysson, K. J. Lindner, J. Kristensen, R. Karlsten, L. L. Gustafsson, J. Persson, J. O. Svensson, I. Oye, G. Antoni, G. Westerberg, and B. Langstrom. Central nervous system effects of subdissociative doses of (s)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers, Clin. Pharmacol. Ther. 58:165-173 (1995).
20. 20. P. M. Bungay, P. F. Morrison, and R. L. Dedrick. Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. Life Sci. 46:105-119 (1990).
21. 21. J. Kornhuber, J. Bormann, M. Hubers, K. Rusche, and P. Riederer. Effects of the I-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel-a human postmortem brain study, Eur. J. Pharmacol. 206:297-300 (1991).
22. 22. C. G. Parsons, R. Gruner, J. Rozental, J. Millar, and D. Lodge. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (I-amino-3,5-dimethyladamantan), Neuropharmacology 32:1337-1350 (1993).
23. 23. G. L. Wenk, W. Danysz, and D. D. Roice. The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis, Neuroreport 7:1453-1456 (1996).
24. 24. L. Stahle, S. Segersvard, and U. Ungerstedt. A comparison between three methods for estimation of extracellular concentrations of exogenous and endogenous compounds by microdialysis. J. Pharmacol. Methods 25:41-52 (1991).
25. 25. P. O. Ekstrom, A. Andersen, D. J. Warren, K. E. Giercksky, and L. Slordal. Determination of extracellular methotrexate tissue levels by microdialysis in a rat model Cancer Chemother. Pharmacol. 37:394-400 (1996).
26. 26. S. Menacherry, W. Hubert, and J. B. Justice. In vivo calibration of microdialysis probes for exogenous compounds, Anal. Chem. 64:577-583 (1992).
27. 27. J. G. Henkel, J. T. Hane, and G. Gianutsos. Structure antiparkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution, J. Med. Chem. 25:51-56 (1982).